LncRNA SNHG15 modulates gastric cancer tumorigenesis by impairing miR-506-5p expression.

Zhiping Chen,Yang Tang,Zhanyu Liu,Lanfeng Wang,Tianyu Zhong,Tao Li,Jinghua Zhong,Baodian Ling

doi:10.1042/bsr20204177

Zhiping Chen, Yang Tang + Show 6 more

Open Access

https://doi.org/10.1042/bsr20204177

Copy DOI

Abstract

The gastric cancer (GC) patients commonly have a poor prognosis due to its invasiveness and distant metastasis. Growing evidence proved that aberrant long non-coding RNAs (lncRNAs) expression contributes to tumor development and progression. LncRNA SNHG15 has been reported to be involved in many different kinds of cancer, while its role in GC remains unclear. In the present study, we found that SNHG15 was up-regulated in GC tissues and cell lines. Silencing SNHG15 suppressed proliferation migration, invasion and promoted apoptosis of AGS cells. More importantly, microRNA-506-5p (miR-506-5p) was predicted as a direct target of SNHG15 by binding its 3′-UTR and further verified using luciferase reporter assay. Meanwhile, the results of rescue experiments revealed that knockdown of miR-506-5p expression reversed the functional effects of SNHG15 silenced cell proliferation, migration, invasion and apoptosis. In conclusion, our findings revealed that SNHG15 executed oncogenic properties in GC progression through targeting miR-506-5p, which might provide a novel target for the GC treatment.

Highlights

Gastric cancer (GC) is the most common malignant human tumor which has high morbidity and mortality
To figure out the role of LncRNA SNHG15 (SNHG15) in HCC, we explored its expression by searching the Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases
SNHG15 was notably up-regulated in GC cell lines (AGS, MNK-45, SNU-1), especially in AGS cells accompany with the normal epithelial cells (GES-1) (Figure 1C)

Summary

Introduction

Gastric cancer (GC) is the most common malignant human tumor which has high morbidity and mortality. There were over 1 million patients diagnosed with GC (5.7% of all cancer diagnoses) and the deaths were over 780000 (8.2% of all cancer-associated mortalities) in 2018 [1,2]. With the development of advanced medical facility in therapeutic strategies, most patients with GC have been diagnosed at advanced stage [3,4,5]. The treatment effect of patients with advanced patients is very poor due to the influence of tumor metastasis and drug resistance. An intensive understanding of the pathogenesis of GC will be helpful in improving diagnosis and therapy for GC patients. Increasing evidence have reported that lncRNAs possess extensive regulatory roles in the occurrence and development of diseases (especially cancers). Number of studies demonstrated that lncRNAs participated in multiple biological processes, including cell proliferation, invasion, apoptosis and differentiation [11,12,13,14]

Objectives

Methods

Results

Conclusion